[1] 刘利容, 吴涛, 詹思延, 等. 利巴韦林的安全性和有效性-Meta分析结果的系统综述[J]. 药物不良反应杂志, 2006, 8(3):184-187. [2] 吴晔, 吴涛, 詹思延,等. 利巴韦林的安全性与利益-风险分析[J]. 药物流行病学杂志, 2006, 15(4): 210-213. [3] 王菡茵, 曾睿. 左氧氟沙星、磷霉素钠和利巴韦林不合理使用致死亡1例[J]. 中国药物警戒, 2011, 8(12):764-766. [4] 吴婷, 吴涛, 詹思延, 等. 利巴韦林致癌、致畸和致突变作用的综合评价[J]. 药物不良反应杂志, 2006, 8(4): 244-247. [5] Yang Y, Zhou X, Gao S, et al. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China[J]. Drug Saf, 2017, 41(1):125-137. [6] Xiang Z, Gonzalez R, Ren L, et al. Prevalence and clinical characteristics of human respiratory syncytial virus in Chinese adults with acute respiratory tract infection[J]. J Med Virol, 2013, 85(2): 348-353. [7] Sinclair S M, Jones J K, Miller R K, et al. The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment[J]. Drug Saf, 2017, 40(12):1205-1218. [8] Roberts S S, Miller R K, Jones J K, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009[J]. Birth Defects Res A Clin Mol Teratol, 2010, 88(7):551-559. [9] Roberts S S. Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry[J]. Gastroenterol Nurs, 2008, 31(6):413-417. [10] 谭芳. 基层医务人员对利巴韦林致畸认知度现状调查[J]. 大家健康(学术版), 2013, 7(8): 3-4. |